why choose us

300×250 Ad Slot

Research Article: Neoadjuvant chemotherapy and immunotherapy followed by radical radiotherapy for locally advanced cervical cancer: efficacy and safety

Date Published: 2026-06-22

Abstract:
This study aimed to evaluate the short-term efficacy and safety of neoadjuvant chemoimmunotherapy (NACI) followed by radical radiotherapy (RR) in patients with locally advanced cervical cancer (LACC). A retrospective analysis was conducted on 60 patients with FIGO 2018 stage IIIA-IVA cervical cancer between June 2022 and July 2024. The experimental group (n=30) received 1–3 cycles of NACI (anti-PD-1/PD-L1 therapy plus platinum-based chemotherapy) followed by RR, which was administered either alone or concurrently with immunotherapy/chemotherapy. The control group (n=30) received RR with or without concurrent chemotherapy. Treatment response was assessed using RECIST 1.1 incorporating gynecological examination. After NACI, the objective response rate (ORR) was 93.3% in the experimental group, increasing to 100% post-radiotherapy. The complete response (CR) rate was comparable between groups (90.0% vs. 86.7%, P = 1.000). With a median follow-up of 20.5 months, the 2-year progression-free survival (PFS) was significantly higher in the experimental group (82.5% vs. 66.0%; HR = 0.364, P = 0.0303), though overall survival (OS) did not differ significantly. The experimental group had a significantly lower incidence of radiotherapy-related intestinal toxicity (20% vs. 60%, P = 0.0033). All immune-related adverse events were grade 1-2. For high-risk LACC, NACI followed by RR was associated with a significantly lower incidence of radiotherapy-related intestinal toxicity. A potential PFS benefit was also observed, although its independent effect could not be confirmed in this limited sample. These findings warrant further investigation in larger prospective trials.

No summary available.

300×250 Ad Slot